CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab

Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes

(2019) Hany E. Marei et al.   BIOCHEMICAL PHARMACOLOGY

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

(2018) Felicitas Rataj et al.   BRITISH JOURNAL OF CANCER

Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells

(2018) Kristin M. Snyder et al.   Frontiers in Immunology

T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G–opsonized target cells

(2016) Maria Michela D'Aloia et al.   CYTOTHERAPY

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies

(2016) Hannah M. Cheeseman et al.   JOURNAL OF VIROLOGY

CD16 and CD32 Gene Polymorphisms May Contribute to Risk of Idiopathic Thrombocytopenic Purpura

(2016) Jiannan Xu et al.   MEDICAL SCIENCE MONITOR

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer

(2016) John Pradeep Veluchamy et al.   PLoS One

OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer

(2015) Benjamin Weixler et al.   Oncotarget

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy

(2015) Sara Alves et al.   Oncotarget

Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β2-Integrin-Mediated Interaction

(2015) Giuseppe Sconocchia et al.   NEOPLASIA

Gene-Modified Human  / -T Cells Expressing a Chimeric CD16-CD3  Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

(2014) F. Ochi et al.   Cancer Immunology Research

T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing

(2013) K. Kudo et al.   CANCER RESEARCH

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Cells Inhibit NK Cell Functions--Letter

(2012) G. Sconocchia et al.   CANCER RESEARCH

Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity

(2012) G. Pietra et al.   CANCER RESEARCH

Natural killer cells in non-hematopoietic malignancies

(2012) Mélanie Desbois et al.   Frontiers in Immunology

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma

(2010) Giuseppe Sconocchia et al.   INTERNATIONAL JOURNAL OF CANCER

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity

(2009) M. Balsamo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE